Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "T2DM" Condition: Type 2 Diabetes Clear all
Completed Phase 3 Interventional Results available

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

NCT03371108
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Gan & Lee Insulin Glargine Injection, Lantus®
Biological
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Industry
Eligibility
18 Years to 75 Years
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
57
States / cities
Birmingham, Alabama • Tuscumbia, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Phase 4 Interventional

Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia

NCT01267448
View directory record Official record
Conditions
Diabetes Mellitus Type 2, Hyperglycemia
Interventions
Glipizide XL, Saxagliptin + Metformin XR, Metformin XR
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Jul 23, 2026, 2:04 PM EDT
Recruiting Not applicable Interventional

Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients

NCT06663813
View directory record Official record
Conditions
Type 2 Diabetes, Hyperglycemia
Interventions
Educational Intervention
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Jul 23, 2026, 2:04 PM EDT
Recruiting Not applicable Interventional

Food as Medicine for HIV and Diabetes

NCT05026723
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, HIV Infections, PreDiabetes
Interventions
MTM + ILI, Standard MTM
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Not applicable Interventional Results available

Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes

NCT01073020
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Allergan Adjustable Gastric Band Surgery, Intensive Medical Diabetes & Weight Management (Why WAIT) - Band Group, Roux-en-Y Gastric Bypass (RYGB) Surgery, Intensive Medical Diabetes & Weight Management (Why WAIT) - Bypass Group
Device · Other · Procedure
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
21 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Jul 23, 2026, 2:04 PM EDT
Recruiting Phase 4 Interventional

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

NCT05708859
View directory record Official record
Conditions
Type II Diabetes, Atherosclerosis
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Matthew J. Budoff
Other
Eligibility
40 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Phase 4 Interventional Results available

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

NCT05114590
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/Lixisenatide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
18
States / cities
Canyon Country, California • Huntington Park, California • Lomita, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Not applicable Interventional

Fresh Carts for Mom's to Improve Food Security and Glucose Management

NCT05979519
View directory record Official record
Conditions
Gestational Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus
Interventions
Fresh Funds for Mom's, Standard Medical care, Medically Tailored Frozen Meals
Behavioral
Lead sponsor
Alison Gustafson
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Lexington, Kentucky • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT01452451
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Ohio City, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Diabetic Patient Health Through Assistive-Reading Technology

NCT05337306
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Health Knowledge, Attitudes, Practice, Literacy
Interventions
GogyUp Reader
Other
Lead sponsor
GogyUp Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
193 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pfizer/IVGTT/Ziprasidone/Olanzapine

NCT00205725
View directory record Official record
Conditions
Schizophrenia, Type 2 Diabetes Mellitus
Interventions
Ziprasidone, Olanzapine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Phase 4 Interventional

Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

NCT03970044
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide 2 MG, Dapagliflozin 10 MG
Drug
Lead sponsor
Consano Clinical Research, LLC
Other
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Shavano Park, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2021 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Not applicable Interventional

Latinos Understanding the Need for Adherence in Diabetes

NCT03983499
View directory record Official record
Conditions
Type 2 Diabetes, Glycemic Control, Cardiovascular Risk Factors, Psychological Distress
Interventions
Special Intervention
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Jul 23, 2026, 2:04 PM EDT
Not listed Phase 2 Interventional

An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy

NCT03279263
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MLR-1023, Placebo
Drug · Other
Lead sponsor
Melior Pharmaceuticals
Other
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)

NCT02722499
View directory record Official record
Conditions
Diabetes Mellitus, Type 2 Diabetes Mellitus, Adult-Onset Diabetes Mellitus, Non-Insulin-Dependent Diabetes Mellitus, Noninsulin Dependent Diabetes Mellitus, Type II
Interventions
High Frequency Financial Incentive, Moderate Frequency Financial Incentive, Low Frequency Financial Incentive
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
21 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Jul 23, 2026, 2:04 PM EDT
Completed No phase listed Observational

A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM

NCT03090464
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Use of digital disease management tool
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
46
States / cities
Birmingham, Alabama • Peoria, Arizona • Surprise, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

NCT05232071
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Interventions
IVA337, Placebo, Empagliflozin
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
Homewood, Alabama • Chandler, Arizona • Conway, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

NCT02769481
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Placebo for Bexagliflozin, Glimepiride, Placebo for Glimepiride
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • Huntington Park, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Jul 23, 2026, 2:04 PM EDT
Terminated Phase 4 Interventional Results available

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

NCT02750930
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide, Auto-injector
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
27
States / cities
Phoenix, Arizona • Fresno, California • Lomita, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients

NCT01221519
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, High Blood Sugar
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Niacin on Intramyocellular Fatty Acid Trafficking in Upper Body Obesity and Type 2 Diabetes Mellitus

NCT03867500
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Niacin, Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

NCT03531905
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia
Interventions
Bempedoic acid + Ezetimibe FDC Oral Tablet, Ezetimibe 10 mg Oral Tablet, Placebo Oral Tablet, Placebo oral capsule
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Lincoln, California • Miami, Florida • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Not applicable Interventional

Effect of Bariatric Surgery on Mechanisms of Type 2 Diabetes

NCT01278823
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
laparoscopic roux en y gastric bypass operation, medical management
Procedure · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Jul 23, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT02009488
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
San Diego, La Jolla, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Jul 23, 2026, 2:04 PM EDT